AngioDynamics (ANGO +2.3%) moves up after FQ2 earnings beat bottom line estimates by a penny on an 89% Y/Y jump in vascular sales. Net profit slipped 15% Y/Y however, as higher input costs and expenses in its oncology division offset the sales gains. The company also lowered its FY13 revenue guidance to between $355M and $360M, down from its October view of revenue of $361M to $ 364M.
AngioDynamics (ANGO +2.3%) moves up after FQ2 earnings beat bottom line estimates by a penny on...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs